Evidence map›Paper›PMID 33045106›Full record

ArticleJournal of the American Geriatrics Society2020

COVID-19 in Older Adults: A Series of 76 Patients Aged 85 Years and Older with COVID-19.

Agathe Vrillon, Claire Hourregue, Julien Azuar, Lina Grosset, Ada Boutelier, Sophie Tan, Michael Roger, Vianney Mourman, Stéphane Mouly, Damien Sène and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Mortality Trends in Pre-COVID-19 and COVID-19 Eras Among Oldest Veterans.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Article
  6. Observational
  7. Increased levels of GM-CSF and CXCL10 and low CD8Immunity & ageing : I & A · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Agathe VrillonUniversité de Paris, INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.ORCID 0000-0002-0761-7885
Claire HourregueCentre de Neurologie Cognitive, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Julien AzuarUniversité de Paris, INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.
Lina GrossetCentre de Neurologie Cognitive, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Ada BoutelierCOVID Unit Féréol, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Sophie TanCOVID Unit Féréol, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Michael RogerCOVID Unit Féréol, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Vianney MourmanMédecine de la Douleur et Médecine Palliative, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France.
Stéphane MoulyDépartement de Médecine Interne, AP-HP, Groupe Hospitalier Lariboisière Fernand-Widal, Hôpital Lariboisière, Paris, France.
Damien SèneDépartement de Médecine Interne, AP-HP, Groupe Hospitalier Lariboisière Fernand-Widal, Hôpital Lariboisière, Paris, France.
Véronique FrançoisGériatrie, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France.
Julien DumurgierCentre de Neurologie Cognitive, AP-HP, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
Claire PaquetUniversité de Paris, INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.
for LRB COVID Group
Hôpital Fernand-Widal · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical presentation and risk factors of death in COVID-19 in oldest adults have not been well characterized.

objectivesTo describe clinical features and outcome of COVID-19 in patients older than 85 years and study risk factors for mortality.

designProspective cohort. PARTICIPANTS AND

settingPatients aged 85 years and older, admitted in noncritical care units at the University Hospital Lariboisière Fernand-Widal (Paris, France) for confirmed severe acute respiratory syndrome coronavirus 2 infection were included and followed up for 21 days. MEASUREMENTS: Clinical and laboratory findings were collected. Cox survival analysis was performed to explore factors associated with death.

resultsFrom March 14 to April 11, 2020, 76 patients (median age = 90 (86-92) years; women = 55.3%) were admitted for confirmed COVID-19. Of the patients, 64.5% presented with three or more comorbidities. Most common symptoms were asthenia (76.3%), fever (75.0%) and confusion and delirium (71.1%). An initial fall was reported in 25.0% of cases, and digestive symptoms were reported in 22.4% of cases. COVID-19 was severe in 51.3% of cases, moderate in 32.9%, and mild in 15.8%. Complications included acute respiratory syndrome (28.9%), cardiac decompensation (14.5%), and hypotensive shock (9.0%). Fatality at 21 days was 28.9%, after a median course of disease of 13 (8-17) days. Males were overrepresented in nonsurvivors (68.2%). In survivors, median length of stay was 12 (9-19.5) days. Independent predictive factors of death were C-reactive protein level at admission and lymphocyte count at nadir.

conclusionSpecific clinical features, multiorgan injury, and high case fatality rate are observed in older adults with COVID-19. However, rapid diagnosis, appropriate care, and monitoring seem to improve prognosis.

Indexed as

COVID-19Aged, 80 and overCohort StudiesComorbidityC-Reactive ProteinFemaleFranceHospitalizationHumansIntensive Care UnitsLymphocyte CountMaleMortalityOutcome and Process Assessment, Health CarePrognosisRisk FactorsC-Reactive Proteinclinical researchCOVID-19mortalityolder adultsrisk factorsSARS-CoV-2

Identifiers

PMID33045106
PMCPMC7675559
OpenAlexW3091932000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.